LeddarTech Appoints David Torralbo, a Seasoned Corporate Lawyer, as Chief Legal Officer

QUEBEC, July 19, 2022 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce the appointment of Mr. David Torralbo as Chief Legal Officer on June 20, 2022.

David has over 20 years of experience specializing in corporate and securities law, public and private M&A, corporate governance, litigation and risk management. Most recently, he served as Chief Legal Officer at Nouveau Monde Graphite (NYSE: NMG and TSXV: NOU) and, before that, as Chief Legal Officer of Atrium Innovations from 2011-2019. Before Atrium, David was a partner in the corporate group at Davies, Ward, Phillips & Vineberg. Earlier in his career, David was an associate in the London, UK office of Clifford Chance and a member of its debt and capital markets team.

David earned his Bachelor of Civil Law (LL.L.) and common law (LL.B.) at the University of Ottawa and has a Bachelor of Commerce (B.Com) from McGill University. He is a member of the Quebec Bar and holds a non-practicing certificate from the Law Society of England & Wales.

“It is a pleasure to welcome David Torralbo as our Chief Legal Officer,” stated Charles Boulanger, CEO of LeddarTech. “David’s expertise in mergers and acquisitions as well as his vast experience and passion for practicing law in the private and public sectors make him an excellent addition to our executive team,” Mr. Boulanger continued. “LeddarTech has, in the past two years, made significant acquisitions enabling the company to accelerate our technology roadmap, particularly in sensor fusion and perception. This was a strategic objective, and David’s background strongly complements our executive team’s dedication to executing on our strategic plan and commitment to exceptional customer service with truly unique sensing solutions that enable ADAS and AD technology,” Mr. Boulanger concluded.

About LeddarTech

Founded in 2007, LeddarTech is a comprehensive end-to-end environmental sensing company that enables customers to solve critical sensing, fusion and perception challenges across the entire value chain. LeddarTech provides cost-effective perception solutions scalable from Level 2 ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types and configurations. LeddarTech also supports LiDAR manufacturers and Tier 1-2 automotive suppliers with key technology building blocks such as LeddarSteer™ digital beam steering and the LeddarEngine™, which is built on LeddarTech’s Leddar™ technology employing patented signal acquisition and processing techniques to generate a richer and cleaner return signal at a lower cost. The LeddarEngine comprises a highly integrated, scalable LiDAR SoC and software combination that enables LiDAR developers and Tier 1-2 automotive suppliers to design their own LiDAR solutions. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 120 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Investor relations contact: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Nyxoah Announces CE Mark Approval for Genio® 2.1

Nyxoah Announces CE Mark Approval for Genio® 2.1

The next generation external activation chip leverages Nyxoah’s scalable platform to continuously enhance patient comfort and therapy efficacy

Mont-Saint-Guibert, Belgium – July 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the DEKRA Notified Body has approved the use of Nyxoah’s next generation Genio® 2.1 system for patients in Europe. As with the recent approval of Genio® 2.1 by the U.S. FDA for use in the DREAM U.S. IDE pivotal study, this CE mark pertains entirely to the external components of the Genio® system and will be available to all patients who have received Genio® implants.

Genio® 2.1 is designed to improve patient comfort and compliance with a new smartphone application and upgraded external activation chip. Genio® 2.1 offers patients daily feedback on therapy usage and the autonomy to adjust stimulation amplitude within pre-defined boundaries. Physicians can fine-tune stimulation amplitude to determine the optimal level of comfort for patients without compromising therapy efficacy. Additional embedded sensors will allow physicians to further tailor therapy stimulation parameters based on patient position and throughout the night.

“Genio® 2.1 embodies the patient-centric design and the scalability of the Genio® platform with features that allow for greater customization of therapy to meet individual patient’s needs,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “Importantly, these additional features are made available without the need for a surgical procedure to replace the implantable component. We are excited to launch Genio® 2.1 in Europe, strengthening our vision to address the needs of OSA patients with and without Complete Concentric Collapse (CCC) and further accelerating market share gains.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment